Moleculin Biotech Inc (MBRX)

May 23, 2025

Moleculin receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa

May 23, 2025

May 23, 2025

Moleculin Biotech Faces Nasdaq Non-Compliance Notice - TipRanks

May 23, 2025

May 23, 2025

Moleculin receives Nasdaq non-compliance notice - Investing.com

May 23, 2025

May 19, 2025

Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved - MSN

May 19, 2025

May 17, 2025

Q2 EPS Forecast for Moleculin Biotech Increased by Analyst - Defense World

May 17, 2025

May 16, 2025

Moleculin Biotech reaches agreement to amend investor warrants - MSN

May 16, 2025

May 16, 2025

MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN

May 16, 2025

May 16, 2025

Moleculin Announces First European Approval for Phase 3 AML Trial - MSN

May 16, 2025

May 15, 2025

Moleculin Biotech’s Earnings Call: Trials and Triumphs - TipRanks

May 15, 2025

May 15, 2025

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025

May 15, 2025

Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

May 15, 2025

May 15, 2025

Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: S - GuruFocus

May 15, 2025

May 15, 2025

Moleculin Biotech Reports Q1 2025 Financial Results - TipRanks

May 15, 2025

May 14, 2025

Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup - MSN

May 14, 2025

May 14, 2025

Transcript : Moleculin Biotech, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com

May 14, 2025

May 14, 2025

Earnings call transcript: Moleculin Biotech reports Q1 2025 updates By Investing.com - Investing.com India

May 14, 2025

May 14, 2025

Earnings call transcript: Moleculin Biotech reports Q1 2025 updates - Investing.com

May 14, 2025

May 14, 2025

Moleculin Reports First Quarter 2025 Financial Results and Provi - GuruFocus

May 14, 2025

May 14, 2025

Moleculin (MBRX) Advances Phase 3 MIRACLE Trial with Global Prog - GuruFocus

May 14, 2025

May 14, 2025

Moleculin (MBRX) Advances Phase 3 MIRACLE Trial with Global Progress | MBRX Stock News - GuruFocus

May 14, 2025

May 14, 2025

Moleculin Biotech reports Q1 EPS (69c) vs ($2.02) last year - TipRanks

May 14, 2025

May 14, 2025

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

May 14, 2025

May 14, 2025

Moleculin's AML Treatment Trial Gets Major EU Expansion as Q1 Results Reveal Timeline for Critical Data - Stock Titan

May 14, 2025

May 13, 2025

MOLECULIN BIOTECH Earnings Results: $MBRX Reports Quarterly Earnings - Nasdaq

May 13, 2025

May 13, 2025

Moleculin Biotech, Inc. SEC 10-Q Report - TradingView

May 13, 2025

May 13, 2025

EMA approves Moleculin’s application for Phase IIb/III AML trial - Yahoo

May 13, 2025

May 12, 2025

Moleculin expands EU trial for leukemia treatment By Investing.com - Investing.com South Africa

May 12, 2025

May 12, 2025

Moleculin Biotech (MBRX) Gains EMA Approval for Pivotal Phase 2B/3 AML Trial | MBRX Stock News - GuruFocus

May 12, 2025

May 12, 2025

Moleculin Receives European Medicines Agency Approval to Expand - GuruFocus

May 12, 2025

May 12, 2025

Moleculin expands EU trial for leukemia treatment - Investing.com Australia

May 12, 2025

May 12, 2025

Moleculin Receives European Medicines Agency Approval To Expand Phase 3 Miracle Clinical Trial - marketscreener.com

May 12, 2025

May 12, 2025

Moleculin Biotech’s Annamycin Trial Approved by EMA - TipRanks

May 12, 2025

May 12, 2025

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial - The Manila Times

May 12, 2025

May 12, 2025

Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

May 12, 2025

May 10, 2025

Moleculin Biotech Cancels Special Meeting Due to Lack of Quorum By Investing.com - Investing.com India

May 10, 2025

May 10, 2025

Moleculin Biotech Cancels Special Meeting Due to Lack of Quorum - Investing.com Australia

May 10, 2025

May 09, 2025

Moleculin Biotech Cancels Special Stockholders Meeting - TipRanks

May 09, 2025

May 09, 2025

Moleculin Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders - Quantisnow

May 09, 2025

May 07, 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - Seeking Alpha

May 07, 2025

May 07, 2025

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast - Seeking Alpha

May 07, 2025

May 07, 2025

Moleculin Biotech to Announce Q1 2025 Financial Results - TipRanks

May 07, 2025

May 07, 2025

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - The Manila Times

May 07, 2025

May 06, 2025

Moleculin Biotech Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView

May 06, 2025

May 06, 2025

Moleculin Biotech (MBRX) Gains WHO Approval for Annamycin's Non- - GuruFocus

May 06, 2025

May 06, 2025

Moleculin Biotech (MBRX) Gains WHO Approval for Annamycin's Non-proprietary Name | MBRX Stock News - GuruFocus

May 06, 2025